These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1246 related articles for article (PubMed ID: 30957945)

  • 1. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcome trials of glucose-lowering medications: an update.
    Home P
    Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcome trials of the newer anti-diabetic medications.
    Acharya T; Deedwania P
    Prog Cardiovasc Dis; 2019; 62(4):342-348. PubMed ID: 31442511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
    Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
    Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
    Sinha B; Ghosal S
    Diabetes Res Clin Pract; 2019 Apr; 150():8-16. PubMed ID: 30794833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
    Giugliano D; Meier JJ; Esposito K
    Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.